AADAC gene expression showed high significant (p<0.001) increases in patients with tumor progression signs (tumor size ≥3 cm, ≥3 lymph nodes, higher grades, and higher stages) and a significant (p<0.05) increase in patients with high metastasis (˃ one organ) while PLEKHS1 and CDKN3 gene expressions showed no significant differences in the same patients compared to those with less tumor progression signs as shown in Table 3. This evidence concerns the gene CDKN3 and neoplasm.